The pathologist is an integral member of the multidisciplinary team central to the successful treatment of bone tumors. The role of the pathologist is to provide morphology-derived information pertaining to diagnosis and status of disease. Communication between all members of this team is vital at all junctures of workup and treatment. During the evaluation of biopsies, critical information from the history, physical examination, and imaging studies should be taken into account and integrated with histological observations to ensure a correct diagnosis. Later on during the course of treatment, the pathologist is called upon to advise the surgeon as to the status of resection margins and adequacy of surgery. And later still, the pathologist provides the medical oncologist with an assessment of the response to preoperative chemotherapy.
In each case, the evaluation of bone specimens requires a systematic approach to specimen preparation and analysis. Mineralization is intrinsic to the structure and function of bone. However, it adds a significant degree of difficulty to bone specimen management; osseous tissues are not easily dissected or cut using traditional techniques. Special methods are required for analyzing bone specimens and sarcomas of bone. Although complex and time consuming, the procedures, when carried out correctly, will reward the pathologist and clinician with accurate, reliable information that provides insight into diagnosis, classification, staging, and treatment efficacy.
Bone Tumor Ewing Sarcoma Aneurysmal Bone Cyst Bone Specimen Preoperative Therapy
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Avigad S, Cohen IJ, Zilberstein J, et al. The predictive potential of molecular detection in nonmetastatic Ewing family of tumors. Cancer. 2006;100:1053–8.CrossRefGoogle Scholar
Ayala AG, Raymond AK, Ro JY, Carrasco CH, Fanning CV, Murray JA. Needle biopsy of primary bone lesions. M.D. Anderson experience. Pathol Annu 1989;24:219–51.PubMedGoogle Scholar
Bjonsson J, McCleod RA, Unni KK, Ilstrup DM, Pritchard DJ. Primary chondrosarcoma of long bones and limb girdles. Cancer. 1998;83:2105–19.CrossRefGoogle Scholar
Dahlin DC, Unni KK. Osteosarcoma of bone and its important recognizable varieties. Am J Surg Pathol. 1977;1:61–72.PubMedCrossRefGoogle Scholar
Dahlin DC, Coventry MB, Scanlon PW. Ewing’s sarcoma: a critical analysis of 165 cases. J Bone Joint Surg Am. 1961;43:185–92.PubMedGoogle Scholar
Dayton AS, Ro JY, Schwartz MR, Ayala AG, Raymond AK. Raymond’s paragraph system: an alternative format for the organization of gross pathology reports and its implementation in an academic teaching hospital. Arch Pathol Lab Med. 2009;133:298–302.PubMedGoogle Scholar
de Alva E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript is an independent determinant of prognosis in Ewing’s sarcoma. J Clin Oncol. 1998;16:1248–55.Google Scholar
Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359:162–5.PubMedCrossRefGoogle Scholar
Dorfman H, Czerniak BA (1998) Bone tumors. Mosby, Saint LouisGoogle Scholar
Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer. 197740:818–31.PubMedCrossRefGoogle Scholar
Fletcher CDM, Unni KK, Mertens F (eds). World Health Organization classification of tumours. Tumours of soft tissue and bone. Pathology & genetics. IARC Press, Lyon: 2002.Google Scholar
Folpe AL, Goldblum JR, Rubin BP, et al. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol. 2005;29:1025–33.PubMedGoogle Scholar
Hallor KH, Micci F, Meis-Kindblom JM, et al. Fusion genes in angiomatoid fibrous histiocytoma. Cancer Lett. 2006;251:158–63.PubMedCrossRefGoogle Scholar
Jaffe HL, Lichtenstein L. Benign chondroblastoma of bone: a reinterpretation of the so-called calcifying or chondromatous giant cell tumor of bone. Am J Pathol. 1942;18:969–91.PubMedGoogle Scholar
Lazar A, Abruzzo LV, Lee S, Pollock RE, Czerniak BA. Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas. Arch Pathol Lab Med. 2006;130:1199–207.PubMedGoogle Scholar
Lewis MM, Kenan S, Yabut SM, Norman A, Steiner G. Periosteal chondroma. A report of ten cases and review of the literature. Clin Orthop. 1990;256:185–92.PubMedGoogle Scholar
Unni KK, Inwards CY. Dahlin’s bone tumors: general aspects and data on 10,165 Cases, 6th edn. Wolters Kluwer/Lippincott, Williams & Wilkins, Philadelphia: 2009.Google Scholar
Unni KK, Inwards CY, Bridge JA, Kindblom LG, Wold LE. Tumors of the bones and joints. AFIP atlas of tumor pathology. Series 4; Fascicle 2. ARP Press, Silver Spring: 2005.Google Scholar
van Doorninck JA, Ji L, Schaub B, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2010;28:1989–94.PubMedCrossRefGoogle Scholar